Compare Incyte Corporation (INCY) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Micron Technology, Inc. — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Micron Technology, Inc. trades at $985.22 (market cap $977.44B). The key difference: Micron Technology, Inc. is far larger — about 42.3× Incyte Corporation's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MU | |
|---|---|---|
Market Cap | $23.11B | $977.44B |
Sector | Health | Technology |
52-Week High | $118.52 | $1.21K |
52-Week Low | $67.38 | $104.88 |
Enterprise Value | $19.13B | $957.80B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Micron Technology (MU) surged 14.36% to $970.82, driven by strong AI memory demand and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 19.56 and net income margin of 55.91%, supported by three consecutive quarterly earnings beats. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels suggesting potential rebound. Recent news highlights AI-driven memory chip demand and strategic customer agreements fueling growth optimism.
Outlook remains bullish due to AI super-cycle tailwinds and projected 2026 revenue of $90.3B, though risks include cyclical semiconductor demand and high valuation multiples. Analyst consensus strongly favors Buy with a $1,550 price target, indicating ~60% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
